Pioneering Scientist and Former CEO of Human Genome Sciences Brings Key Expertise to Grace’s Board

EAST BRUNSWICK, N.J., June 22, 2018 /PRNewswire/ — Grace Therapeutics, a clinical stage biopharmaceutical company focused on rare and orphan diseases, announced today that William Haseltine has been appointed to the company’s Board of Directors. Dr. Haseltine is currently Chairman and President of ACCESS Health International, Inc. and Chairman of the Haseltine Foundation for Science and the Arts. He is the Founder of Human Genome Sciences, Inc. and served as its Chairman and CEO for twelve years.  He is also the founder of several other successful biotechnology companies. Eight pharmaceutical products from companies that he started are currently approved by US and international regulatory agencies.

“Having spent time with Bill over the past few years, I appreciate and value his broad strategic skills and extensive experience as one of the industry’s foremost leaders,” said Vimal Kavuru, Co-Founder and Chairman of Grace. “I am delighted to welcome Bill to our Board. Our team looks forward to working closely with him as we develop and commercialize innovative products and build a world class biopharmaceutical company.”

“I am honored to serve on Grace’s Board of Directors,” said Dr. Haseltine, “and am looking forward to helping the Board and management team advance their vision of improving the standard of care for many important, but inadequately treated diseases.”

“We are assembling a Board that is expertly positioned to guide us through our rapid growth and promising future by bringing innovative therapeutics that improve patient outcomes,” said George Kottayil, PhD, Co-Founder and Chief Executive Officer, Grace Therapeutics. “Bill’s unique and remarkable background in cutting-edge research and enterprise building will be invaluable to Grace as we continue to advance our business strategy and address unmet needs across a number of therapeutic areas.”

Read the entire article

Originally published in Cision PR Newswire (June 22, 2018)